Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.

Area of Science:

• Bioinformatics
• Cancer Genomics
• Pharmacogenomics

Background:

• Identifying genetic drivers of tumor cell chemoactivity is crucial for anticancer drug development.
• Existing methods face challenges in linking gene expression to drug response.
• Discovering biomarkers for compound efficacy and toxicity is vital.

Purpose of the Study:

• To develop and validate a novel pathway-centric data mining procedure for analyzing gene expression and chemoactivity.
• To identify subsets of pathway genes that discriminate chemo-sensitive and chemo-insensitive tumor cell types.
• To improve the prediction accuracy of tumor cell chemoactivity using gene expression profiles.

Main Methods:

• Utilized self-organizing maps (SOMs) and pathway-centric analyses on NCI60 gene expression and chemoactivity data.
• Applied Linear Discriminant Analysis (LDA) to quantify the accuracy of discriminating genes.
• Employed Gene Set Enrichment Analysis (GSEA) to evaluate discriminating genes and reveal cellular genetic landscapes.

Main Results:

• The pathway-centric method achieved 15% higher prediction accuracies using 30% fewer genes compared to conventional correlation methods.
• Identified key over- and under-expressed pathway genes critical for compound tumor cell chemoactivity.
• Demonstrated robust results across different microarray platforms and provided literature-based validation.

Conclusions:

• The proposed pathway-centric approach offers a more efficient and accurate method for identifying biomarkers of drug response.
• This strategy reveals a focused genetic landscape important for anticancer drug efficacy.
• The findings support the development of targeted anticancer therapies based on specific gene expression profiles.